[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Baker Heart and Diabetes Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":195},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,72,105,128,147,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100467391","risk-guided-disease-management-plan-to-prevent-cad-in-patients-treated-with-previous-cancer-100467391",false,"NCT05366153","Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer","Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer (REDEEM-CAD)","REDEEM-CAD","Inclusion Criteria:\n\nA history of cancer \\>5 y ago associated with potential cardiotoxicity from chemotherapy and\u002For radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer).\n\nExclusion Criteria:\n\n* Unable to provide written informed consent to participate in this study\n* Known coronary artery disease at recruitment\n* History of previous coronary artery disease\n* Inability to acquire interpretable CT images\n* Contraindications\u002FIntolerance to or already taking statin therapy\n* Oncologic (or other) life expectancy \\\u003C12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial",true,"ALL","40 Years","70 Years",{"count":22,"type":23},748,"ESTIMATED","OBSERVATIONAL","REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy \\>5 years ago.",[27],"Coronary Artery Disease","RECRUITING","2025-11-27",{"date":31,"type":32},"2025-12-04","ACTUAL",{"date":34,"type":32},"2023-10-18",{"date":36,"type":23},"2026-05",{"name":38,"class":39},"Baker Heart and Diabetes Institute","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":18,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100482175","use-of-artificial-intelligence-guided-echocardiography-to-assist-cardiovascular-patient-management-100482175","NCT05558605","Use of Artificial Intelligence-Guided Echocardiography to assIst cardiovascuLar Patient managEment","AGILE-Echo","Inclusion Criteria:\n\n* Age \\>45 years\n* eligible for Medicare\n* exercise intolerance or cardiovascular (CV) risk factors\n\nExclusion Criteria:\n\n* Known HF or HVD\n* situations where cardio-protection is already indicated (eg. known CAD)\n* comorbid conditions with life expectancy \\\u003C2 years\n* inability to provide written informed consent","45 Years",{"count":50,"type":23},612,"INTERVENTIONAL",[53],"NA","Heart Failure and valvular heart disease are disproportionate problems in rural and remote Australia (RRA). Echocardiography is the best imaging investigation, and essential for management, but access to this essential test shows huge geographic variations, primarily because of dependence on expert acquisition. This trial seeks to demonstrate the effectiveness of artificial intelligence-based echocardiography for triage and management of patients with known or suspected heart disease in RRA.",[56,57],"Heart Failure","Valve Heart Disease",[59,60,61,62],"Artificial intelligence","Echocardiography","Heart failure","Valve disease","2025-10-16",{"date":65,"type":32},"2025-10-20",{"date":67,"type":32},"2023-02-24",{"date":69,"type":23},"2026-06-30",{"name":38,"class":39},1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":80,"minAge":48,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":51,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":71},"100587218","exercise-to-improve-neurovascular-function-in-breast-cancer-survivors-100587218","NCT06925529","Exercise to Improve Neurovascular Function in Breast Cancer Survivors","Protecting Neurovascular Function In lOng-term Breast caNcer Survivors With ExercisE tRaining - The PIONEER Study","PIONEER","Inclusion Criteria:\n\n* Female\n* Aged 45 - 75 years old at study enrolment\n* Diagnosed with stage 1 - 3 breast cancer 5 - 10 years prior to study enrolment\n* Have received potentially toxic chemotherapy, including:\n\n  * Anthracycline (any dose)\n  * Trastuzumab (Herceptin) in breast-cancer with the HER2 mutation OR\n  * Tyrosine kinase inhibitors (e.g. sunitinib) OR\n  * Left chest radiotherapy\n* ≥ 1 'traditional' CVD risk factor (I.e., Hypertension, dyslipidaemia, diabetes, obesity, smoking or family history of CVD) (Mehta et al., 2023)\n* 'Physically inactive', not meeting Australian physical activity guidelines for adults or regularly participating in structured exercise training (Care, 2024).\n* Eligible for Medicare\n* Willing to provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Diagnosed CVD or stage B heart failure\n* Diagnosed neurocognitive or cerebrovascular disease\n* Diagnosed atrial fibrillation or cardiac arrythmia\n* BMI ≤ 18.4 kg∙m2\n* Any other contraindications to exercise testing and training that make participation in this study unsafe, determined through medical screening\n* Unable to speak and understand the English language\n* Contraindication to brain MRI\n* Participating in another clinical research trial where randomized treatment would be unacceptable\n* Oncologic (or other) life expectancy ≤ 12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Principal Investigator) that it is not appropriate for the patient to participate in this trial.","FEMALE","75 Years",{"count":83,"type":23},40,[53],"Study Rationale:\n\nBreast cancer survivors are more likely to develop cardiovascular disease (CVD) or neurocognitive disease than age-matched counterparts without a history of cancer diagnosis. Some anti-cancer treatments cause damage to the cells of heart and the walls of blood vessels, which may exacerbate neurovascular dysfunction and cancer-related cognitive impairment (symptoms such as 'chemo-brain'), as well as accelerating the onset of neurocognitive disease. Therefore, effective policies and therapeutic strategies are needed to minimize neurovascular dysfunction and neurocognitive disease in at-risk populations like breast cancer survivors.\n\nRegular exercise training is effective in slowing or preventing the development of CVD. Furthermore, higher fitness levels are associated with lower dementia risk in older adults, which may be due to better neurovascular function. However, whether exercise training incorporated into a Cardio-Oncology Rehabilitation and Exercise (CORE) programme can improve neurovascular function in breast cancer survivors is currently unknown. Therefore, the primary aim of this study will be to determine the effect of a CORE programme on neurovascular function in long-term breast cancer survivors.\n\nStudy Description:\n\nThis study will be a randomised controlled trial to investigate the effect of a CORE programme on neurovascular function in long-term breast cancer survivors.\n\nParticipants will complete a series of baseline assessments, including lifestyle questionnaires, a cognitive function assessment, dual-energy x-ray absorptiometry (DXA), a cardiopulmonary exercise test (CPET), ultrasound assessments of arterial stiffness and vascular function, and brain magnetic resonance imaging (MRI). Furthermore, participants will wear a blood pressure monitor at home for 24 hours, and a physical activity monitor for seven days.\n\nFollowing completion of baseline assessments, participants will be randomised to either the CORE program or a 'usual care' group. The CORE program will include a 6-month exercise training program supervised by an Exercise Physiologist at the Baker Heart and Diabetes Institute. The usual care group will carry on with healthcare from their usual healthcare provider(s) for 6 months.\n\nParticipants will then complete two follow-up study visits following completion of the 6-month intervention period, with identical procedures to the baseline study visits.\n\nStudy Duration:\n\nThis study involves two baseline study visits in month 1, followed by two study visits in month 7. Participants randomised to the CORE program will be asked to attend the Baker Heart and Diabetes Institute on a weekly basis for supervised exercise training sessions. However, the supervised exercise training sessions will be provided by a mix of in-person, video-conferencing and tele-health modes depending on each participants availability and needs.",[87],"Breast Cancer Survivorship",[89,90,91,92,93,94,95],"Breast Cancer","Survivorship","Neurovascular Function","Cerebral Blood Flow","Cardio-Oncology","Exercise Training","Neurocognitive Function","NOT_YET_RECRUITING","2025-09-30",{"date":99,"type":32},"2025-10-02",{"date":101,"type":23},"2025-11-03",{"date":103,"type":23},"2026-08-29",{"name":38,"class":39},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":17,"sex":18,"minAge":112,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":51,"phases":116,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":71},"100438018","persistent-cardiovascular-effects-of-covid-19-viral-infection-trial-perceive-100438018","NCT04983823","Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)","Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE): A Randomised Controlled Trial of the Role of Optimal Cardioprotection Strategies to Prevent Heart Failure","Inclusion Criteria:\n\n1. History of COVID-19 infection\n2. Live within a geographically accessible area for follow-up\n\nExclusion Criteria:\n\n1. Valvular stenosis or regurgitation of \\>moderate severity\n2. History of previous heart failure (baseline New York Heart Association (NYHA) classification \\>2)\n3. Inability to acquire interpretable images (identified from baseline echo)\n4. Contraindications to beta blockers or angiotensin-converting enzyme inhibitors\n5. Oncologic (or other) life expectancy \\\u003C12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial\n6. Already taking both angiotensin converting enzyme inhibitors\u002F angiotensin receptor blockers and beta blockers, or intolerance (or allergy) to both.\n7. Mobility impairment that would impact participants' ability to perform exercise\n8. Unable to provide written informed consent to participate in this study","50 Years","85 Years",{"count":115,"type":23},820,[53],"This is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors \\>50 years old.\n\nThe overall goal of this study to identify the feasibility and value of risk-guided medical therapy and exercise intervention in COVID-19 survivors.",[56],[61,120],"COVID",{"date":122,"type":32},"2025-10-03",{"date":124,"type":32},"2021-11-18",{"date":126,"type":23},"2025-12-30",{"name":38,"class":39},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":113,"enrollmentInfo":134,"targetDuration":4,"studyType":51,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":71},"100436397","risk-guided-disease-management-plan-to-prevent-heart-failure-in-patients-treated-with-previous-chemotherapy-redeem-100436397","NCT04962711","Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)","Inclusion Criteria:\n\n1. History of cancer \\> 10 years ago\n2. Have received potentially toxic chemotherapy Anthracycline (any dose) Trastuzumab (Herceptin) in breast-cancer with the HER2 mutation OR Tyrosine kinase inhibitors (e.g. sunitinib) OR Left chest radiotherapy\n\nExclusion Criteria:\n\n1. Ejection fraction at baseline echo \\\u003C50%\n2. Valvular stenosis or regurgitation of \\>moderate severity\n3. History of previous heart failure (baseline New York Heart Association (NYHA) classification \\>2)\n4. Systolic BP \\\u003C110 mmHg\n5. Pulse \\\u003C60\u002Fminute if not on beta blocker\n6. Inability to acquire interpretable images (identified from baseline echo)\n7. Contraindications to beta blockers or angiotensin-converting enzyme inhibitors\n8. Oncologic (or other) life expectancy \\\u003C12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial\n9. Already taking both angiotensin converting enzyme inhibitors\u002Fangiotensin receptor blockers and beta blockers, or intolerance (or allergy) to both.\n10. Unable to provide written informed consent to participate in this study",{"count":135,"type":23},685,[53],"This is a prospective study in which a process of identifying and reducing heart failure (HF) risk will be applied to cancer survivors \\>55 years old with chemotherapy \\>5 years ago.\n\nThe overall goal of this study to identify the feasibility and value of risk-guided cardiac rehabilitation (exercise, risk factor modification, and behavioural support) as a component of survivorship care.",[56],"2025-05-26",{"date":141,"type":32},"2025-05-31",{"date":143,"type":32},"2023-03-30",{"date":145,"type":23},"2025-12-31",{"name":38,"class":39},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":51,"phases":157,"briefSummary":158,"conditions":159,"keywords":160,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":167,"locationsCount":71},"100573178","echo-acquisition-despite-geographic-separation-by-replication-of-human-movements-eager-100573178","NCT06742905","Echo Acquisition Despite Geographic Separation by Replication of Human Movements (EAGER)","Echocardiographic Acquisition With Geographic Separation of Patients and Sonographers With Roboot Assistance (EAGER)","EAGER","Inclusion Criteria:\n\n* Having a conventional echocardiogram\n\nExclusion Criteria:\n\n* Declined consent to undergo both examinations",{"count":156,"type":23},50,[53],"Echocardiography is a cornerstone of modern cardiology management, but access in rural and remote areas is limited. We have developed a robot (\"Edler\" named after the originator of echocardiography) which enables a sonographer to complete an examination at a distance. This study seeks to compare the images obtained by both methods, the completeness of the exam over a feasible time, and to identify particular components of the exam that are difficult to obtain using the robot.",[60],[60],"2024-12-16",{"date":163,"type":32},"2024-12-19",{"date":165,"type":23},"2025-01-15",{"date":145,"type":23},{"name":38,"class":39},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":18,"minAge":176,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":51,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":71},"100522868","reducing-cognitive-impairment-by-management-of-heart-failure-as-a-modifiable-risk-factor-100522868","NCT06088212","Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor","Reducing Cognitive Impairment by Management of Heart Failure as a Modifiable Risk Factor: the Cog-HF Trial","Cog-HF","Inclusion Criteria:\n\n1. Hospitalised with HF as primary or secondary diagnosis.\n2. At least mild cognitive impairment (CI) based on Montreal Cognitive Assessment (MoCA) on hospital discharge.\n\nExclusion Criteria:\n\n1. Unable to provide written consent; requiring palliative care; or participating in another RCT\n2. Recovery of cognitive function shortly after hospital discharge: to ensure that we only include patients with \"true\" CI, any patients with a repeated MoCA\\>25 at 2 weeks post-discharge will be excluded.\n3. Terminal illness (eg. cancer) that may influence 12-month prognosis.","18 Years",{"count":178,"type":23},168,[53],"This study will test the feasibility and effectiveness of an innovative model of care for cognitively impaired patients with heart failure. This program aims to improve cognition, reduce dementia risk and cardiovascular events, and will be supported by innovative digital technology for wide scale rollout and implementation. Findings from this research will transform the way healthcare is delivered to cognitively impaired patients with heart disease who have a very high risk of developing dementia.",[56,182,183,184,185,186],"Cognitive Impairment","Dementia","Left Ventricular Dysfunction","Cognitive Change","Cognitive Decline","2024-08-09",{"date":189,"type":32},"2024-08-12",{"date":191,"type":32},"2024-07-01",{"date":193,"type":23},"2026-07",{"name":38,"class":39},""]